Last updated: August 1, 2026
Renova is a prescription topical cream containing tretinoin 0.02%, approved in the United States for the mitigation of fine facial wrinkles in patients using comprehensive skin-care and sun-avoidance programs. Its original clinical development is complete. No current pivotal trial program or novel regulatory expansion materially changes Renova's profile. The brand competes in a mature market against generic tretinoin, cosmetic retinol products, dermatology procedures and newer topical anti-aging products.
Renova's commercial outlook is constrained by generic substitution, limited differentiation from other tretinoin creams and the absence of meaningful current market exclusivity. Revenue is likely to remain concentrated in branded prescriptions, dermatology distribution and patients who specifically request the Renova name.
What is Renova and what does it treat?
Renova is a topical emollient cream containing tretinoin 0.02%. The product is indicated for the mitigation of fine facial wrinkles associated with photodamaged skin. The FDA approval does not make Renova a general anti-aging product or a treatment for all manifestations of photoaging.
| Attribute |
Renova profile |
| Active ingredient |
Tretinoin |
| Strength |
0.02% |
| Dosage form |
Topical cream |
| U.S. indication |
Mitigation of fine facial wrinkles |
| FDA pathway |
New Drug Application |
| U.S. prescription status |
Prescription |
| Primary specialty |
Dermatology |
| Main alternatives |
Generic tretinoin, retinol, resurfacing procedures and injectables |
| Regulatory differentiation |
Cosmetic photoaging indication rather than acne indication |
Tretinoin is a retinoid derived from vitamin A. It promotes epidermal turnover and affects collagen-related processes in photodamaged skin. The product is generally used once daily, with gradual improvement over several months. Common local reactions include erythema, peeling, dryness, burning and increased sensitivity to sunlight. The FDA label instructs patients to use sun protection and discontinue use if severe irritation develops (U.S. Food and Drug Administration [FDA], 2023).
What clinical trials supported Renova approval?
Renova's approval was based on controlled clinical studies in patients with photodamaged facial skin and fine wrinkles. The trials evaluated tretinoin cream 0.02% against vehicle cream over approximately six months. Investigators assessed changes in fine facial wrinkles and other signs of photoaging using clinical grading methods.
The development program established that Renova could produce a modest but statistically significant improvement in fine wrinkles compared with vehicle. The results were not equivalent to the rapid structural changes associated with botulinum toxin, dermal fillers, laser resurfacing or surgical procedures.
What did the Renova clinical trials show?
The clinical evidence supports several conclusions:
- Improvement develops gradually rather than immediately.
- Results are more evident after sustained use.
- Erythema, dryness, scaling and burning are common during treatment.
- Sun exposure can worsen irritation and reduce treatment benefit.
- The pivotal evidence addressed fine wrinkles, not deep rhytides, skin laxity or volume loss.
- Tretinoin efficacy is dependent on adherence and a broader photoprotection regimen.
The Renova label states that clinical improvement may require several months and that treatment response varies across patients. The product should be applied as a thin layer to the face at night, with avoidance of the eyes, mouth, nasal creases and irritated skin (FDA, 2023).
Are there new Renova clinical trials or FDA expansions?
No major current clinical-trial program has been associated with Renova's original 0.02% formulation. The product's development cycle is mature, and the principal clinical question has already been answered through the original vehicle-controlled trials.
Clinical research involving tretinoin continues in other areas, including acne, combination dermatology products, drug delivery and photoaging research. Those studies do not automatically expand Renova's approved indication. A new indication, concentration or delivery system would require separate regulatory support.
| Development area |
Renova status |
| Fine facial wrinkles |
Approved indication |
| Acne vulgaris |
Established for other tretinoin products, not the Renova wrinkle indication |
| Deep wrinkles |
Not an approved Renova claim |
| Skin laxity |
Not an approved Renova claim |
| Combination with procedures |
Common in practice, but not equivalent to an FDA-approved Renova combination indication |
| New Renova formulation |
No material public clinical program identified through the latest established regulatory record |
What is the FDA and Orange Book status of Renova?
Renova was approved under U.S. NDA 020941. The product is a prescription tretinoin cream rather than a biologic, so biosimilar substitution rules do not apply.
The FDA Orange Book is relevant because it identifies approved drug products and patent or exclusivity information submitted for listed products. Renova's commercial position is different from that of a recently approved medicine with active regulatory exclusivity. Its key commercial exposure comes from generic tretinoin products and therapeutic substitution rather than biosimilar competition.
Does Renova have FDA exclusivity?
Renova's original approval-era exclusivity has expired. No current regulatory exclusivity is generally associated with the long-established 0.02% cream indication. Any later product-specific exclusivity would depend on a new qualifying approval, such as a new formulation or clinical indication.
What patents protect Renova?
The original composition and formulation patents associated with tretinoin cream products are historical rather than current barriers to generic entry. The relevant protection for Renova has expired or no longer provides a meaningful broad market barrier.
A patent review should distinguish between:
- Expired formulation or composition patents.
- Patents covering other tretinoin concentrations or delivery systems.
- Method-of-use patents for different dermatologic indications.
- Device or packaging patents.
- Current listing status for the specific NDA and strength.
A patent covering a separate tretinoin formulation would not automatically protect Renova 0.02% cream. Likewise, a patent covering acne treatment would not necessarily block a generic product used for facial wrinkles.
How many patents cover Renova and when does Renova lose exclusivity?
Renova does not have a current patent estate comparable to a newly launched specialty drug. The practical loss of exclusivity occurred years ago through expiration of the original patent and regulatory protection, followed by generic availability.
| Exclusivity category |
Current commercial effect |
| Original product patent |
Expired or no longer commercially blocking |
| Original FDA exclusivity |
Expired |
| Active ingredient protection |
Not available for the mature tretinoin molecule |
| Formulation protection |
Product-specific and largely historical |
| Method-of-use protection |
May apply to separate uses, but does not recreate broad Renova exclusivity |
| Regulatory exclusivity for current Renova indication |
No material active exclusivity identified |
Which companies compete with Renova?
Renova competes across several layers rather than against one direct branded rival.
Generic tretinoin manufacturers
Generic tretinoin creams and gels are the closest pharmaceutical substitutes. Manufacturers may offer different concentrations, vehicles and dosage forms. The most direct competitive advantages are lower price, formulary access and pharmacy substitution.
Generic products can differ in tolerability because vehicle characteristics affect spreadability, irritation, dryness and patient adherence. These differences can preserve limited demand for a branded or premium formulation, but they rarely support durable premium pricing without active brand promotion.
Cosmetic retinol products
Over-the-counter retinol products compete for consumers seeking anti-aging benefits without a prescription. Retinol is generally less potent than tretinoin because it requires conversion through intermediate metabolites, but it has broader retail access and often better consumer acceptance.
Medical procedures
Botulinum toxin, dermal fillers, fractional lasers, chemical peels, radiofrequency devices and other procedures address wrinkles through different mechanisms. They compete with Renova for the same discretionary anti-aging spending, even though they are not pharmacologic substitutes.
| Competitor category |
Relative advantage over Renova |
Relative limitation |
| Generic tretinoin |
Lower cost and broad availability |
Vehicle variability and irritation |
| OTC retinol |
Easy access and broad retail distribution |
Generally lower potency |
| Botulinum toxin |
Fast effect for dynamic wrinkles |
Requires procedures and repeat treatment |
| Dermal fillers |
Immediate volume correction |
Injection risks and higher cost |
| Laser resurfacing |
Greater procedural resurfacing effect |
Recovery time and expense |
| Cosmetic moisturizers |
High tolerability and convenience |
Limited evidence for tretinoin-level efficacy |
What is the market size and revenue exposure for Renova?
Public company filings generally do not report Renova revenue as a separate line item. The product is typically grouped within broader dermatology, aesthetics or prescription pharmaceutical categories. That prevents a reliable standalone historical revenue series from public filings.
Renova's revenue exposure is determined by five variables:
- Prescription volume for the wrinkle indication.
- Brand retention relative to generic substitution.
- Net price after rebates and pharmacy discounts.
- Dermatologist prescribing behavior.
- Consumer willingness to pay for a branded topical.
The product has a narrower market than generic tretinoin for acne because its approved indication is cosmetic photoaging. Many patients using tretinoin for wrinkles may receive an acne-labeled generic product, use an off-label regimen, or choose OTC retinol instead.
What is the Renova market forecast?
A practical forecast should treat Renova as a mature, low-growth branded dermatology product rather than a pipeline asset. The following scenario is an analytical market model, not reported company guidance.
| Scenario |
Volume trend |
Net-price trend |
Indicative five-year sales direction |
| Downside |
Decline of 8% to 12% annually |
Flat to down |
40% to 60% below current base |
| Base case |
Decline of 3% to 7% annually |
Flat to modest increase |
15% to 30% below current base |
| Upside |
Flat volume |
Low-single-digit increase |
Flat to 15% growth |
The base case assumes continued generic substitution, stable demand for prescription retinoids and limited new investment in Renova-specific promotion. The upside case requires stronger brand retention, a differentiated vehicle, higher dermatology adoption or a successful reformulation. A new formulation with improved tolerability could support a premium, but it would require clinical, regulatory and commercial investment.
How strong is the Renova patent estate?
Renova's patent estate is weak as a current barrier to entry. The active ingredient is mature, generic manufacturers are established, and the product does not depend on a difficult-to-replicate biologic manufacturing process.
The stronger forms of protection would be formulation-specific rather than molecule-specific. Examples could include a novel emulsion, controlled-release system, stabilizer package or delivery technology. Those rights would protect only the claimed formulation and would not necessarily prevent generic tretinoin products in different vehicles.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers are moderate rather than high. Tretinoin is a small molecule with established topical manufacturing methods. The main technical issues are:
- Uniform drug distribution in the cream.
- Stability and light sensitivity.
- Particle size and suspension control.
- Preservation and packaging.
- Consistent topical release.
- Skin irritation and vehicle performance.
These requirements create quality-control obligations but do not resemble the manufacturing barriers associated with monoclonal antibodies, cell therapies or complex injectables.
What generic launch risks exist for Renova?
The principal generic-entry risk is continuing erosion rather than a single future launch event. Generic tretinoin products can capture prescriptions through substitution, lower out-of-pocket cost and payer preference.
Potential launch scenarios include:
- Further pharmacy substitution into generic tretinoin cream.
- Increased prescribing of generic tretinoin under acne labeling for off-label photoaging use.
- Growth of online dermatology services dispensing generic products.
- Expansion of OTC retinol and retinaldehyde products.
- Premium competition from better-tolerated topical retinoid formulations.
Paragraph IV litigation risk appears limited for the mature Renova product because the central patent barriers are historical. A new Paragraph IV dispute would be more likely to involve a later formulation, delivery technology or separate branded tretinoin product than the original Renova cream.
What litigation or settlement agreements affect Renova?
No major active litigation or settlement agreement is central to the current commercial outlook of Renova's original 0.02% cream. The key legal issue is loss of exclusivity and generic competition, not a pending high-value patent dispute.
Any diligence on a specific manufacturer should separately review:
- FDA Orange Book patent listings for the relevant NDA.
- Abbreviated New Drug Application approvals.
- Paragraph IV certifications.
- District court complaints and settlements.
- State substitution rules.
- Promotional claims concerning cosmetic improvement.
- Product liability and adverse-event litigation.
Does Renova face biosimilar risk?
No. Renova is a small-molecule topical drug, not a biologic. Biosimilar pathways do not apply. Its competitive risk comes from generic tretinoin, therapeutic substitution and nonprescription retinoids.
How does Renova compare with generic tretinoin?
| Factor |
Renova |
Generic tretinoin |
| Brand recognition |
Higher among dermatology patients |
Low to moderate |
| Price |
Usually higher |
Usually lower |
| Approved wrinkle indication |
Yes, for Renova labeling |
Product-specific labeling varies |
| Vehicle consistency |
Brand-specific |
Manufacturer-specific |
| Payer preference |
Often weaker |
Usually stronger |
| Patent protection |
No meaningful current broad barrier |
Benefits from mature generic market |
| Commercial growth potential |
Limited |
Volume growth possible through substitution |
Key Takeaways
- Renova is tretinoin 0.02% cream approved for mitigation of fine facial wrinkles.
- Its pivotal clinical evidence is mature and supports gradual improvement over approximately six months.
- No major new Renova-specific clinical program or FDA expansion drives the current outlook.
- Original patent and regulatory exclusivity have expired or no longer provide a meaningful market barrier.
- Generic tretinoin is the principal pharmaceutical competitor.
- OTC retinol and aesthetic procedures expand competitive pressure.
- Biosimilar risk is not relevant because Renova is a small-molecule topical drug.
- Standalone Renova revenue is generally not disclosed publicly.
- The base-case outlook is gradual revenue erosion, driven by generic substitution and limited product differentiation.
- A reformulated, better-tolerated vehicle would offer the clearest route to renewed commercial value.
Frequently Asked Questions
Is Renova the same as tretinoin?
Renova is a branded product containing tretinoin 0.02% cream. Other tretinoin products may use different strengths, vehicles and FDA-approved indications.
Can Renova treat acne?
Renova's labeled indication is fine facial wrinkles associated with photodamaged skin. Tretinoin products approved for acne are separate products and may use different strengths or dosage forms.
Is Renova stronger than retinol?
Tretinoin is generally pharmacologically more potent than OTC retinol because retinol requires metabolic conversion before exerting retinoid activity. Tolerability, adherence and formulation also affect clinical results.
Will a generic replace Renova?
Generic substitution is a continuing risk because generic tretinoin is available at lower cost. Brand retention may persist where patients or prescribers prefer Renova's vehicle, labeling or established brand identity.
Is Renova still commercially attractive for licensing?
The original product has limited licensing attractiveness as a mature brand. The stronger opportunity would involve a differentiated tretinoin delivery system, improved tolerability, a new indication or a protected combination product.
References
-
U.S. Food and Drug Administration. (2023). Renova (tretinoin) cream, 0.02% prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. National Library of Medicine. (2024). DailyMed: Renova and tretinoin topical product labeling. National Library of Medicine.
-
U.S. Food and Drug Administration. (1996). Renova NDA 020941 approval history. FDA Drugs@FDA database.
-
Kang, S., Voorhees, J. J., & others. (1998). Topical tretinoin in the treatment of photoaged skin. Journal of the American Academy of Dermatology, 39(2), S1-S11.
